Evidence map›Paper›PMID 34094949›Full record

ArticleFrontiers in oncology2021

MicroRNA-486-5p Suppresses Lung Cancer

Lei Ding, Wu Tian, Hui Zhang, Wanqiu Li, Chunyu Ji, Yuanyuan Wang, Yanli Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Prognostic Significance ofInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lei DingLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Wu TianDepartment of General Surgery, Orthopedics Hospital of Guizhou Province, Guiyang, China.
Hui ZhangLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Wanqiu LiLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Chunyu JiDepartment of Thoracic Surgery, Shanghai Chest Hospital, Jiaotong University Medical School, Shanghai, China.
Yuanyuan WangDepartment of Respiratory and Critical Care Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
Yanli LiLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Shanghai University · CNShanghai Chest Hospital · CNShanghai East Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is one of the central causes of tumor-related deaths globally, of which non-small cell lung cancer (NSCLC) takes up about 85%. As key regulators of various biological processes, microRNAs (miRNAs) have been verified as crucial factors in NSCLC. To elucidate the role of miR-486-5p in the mTOR pathway, we investigated its role in NSCLC and related signaling. Our results confirmed that miR-486-5p was downregulated in most of human NSCLC tissue samples and cell lines. Further study confirmed that it inhibited NSCLC through repression of the mTOR pathway

Indexed as

miR-486-5pmTOR signalingNSCLCp70S6KRSK

Identifiers

PMID34094949
PMCPMC8172781
OpenAlexW3160381671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.